Analysts Offer Insights on Healthcare Companies: Nucana Plc (NASDAQ: NCNA), Entasis Therapeutics Holdings Inc (NASDAQ: ETTX) and Trillium Therapeutics (NASDAQ: TRIL)

By Carrie Williams

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nucana Plc (NCNAResearch Report), Entasis Therapeutics Holdings Inc (ETTXResearch Report) and Trillium Therapeutics (TRILResearch Report).

Nucana Plc (NCNA)

H.C. Wainwright analyst Ram Selvaraju initiated coverage with a Buy rating on Nucana Plc today and set a price target of $20. The company’s shares closed last Monday at $6.95, close to its 52-week low of $6.80.

Selvaraju said:

“We have valued NuCana on a discounted cash flow (DCF) basis, which yields a $624M projected enterprise value as of mid-2020. Our calculations rely upon a 60% probability of approval for Acelarin across both front-line BTC and fourth-line 30% probability of approval for NUC-3373 in the mCRC indication. We utilize a 12% discount rate and 17% effective corporate income tax rate, along with a 1% terminal growth rate.”

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -10.4% and a 28.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Stealth Biotherapeutics Corp.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nucana Plc with a $27.50 average price target.

See today’s analyst top recommended stocks >>

Entasis Therapeutics Holdings Inc (ETTX)

In a report released today, Ed Arce from H.C. Wainwright initiated coverage with a Buy rating on Entasis Therapeutics Holdings Inc and a price target of $18. The company’s shares closed last Monday at $8.25.

Arce wrote:

“916-3963, POS Risk-adj value Full value SUL-DUR – ABC Shares outstanding 13,135 As of August 6, 2019 Zoliflodacin – Current share price $8.25 Discount rate 14.0% ETX0282CPDP – cUTI 20% $1.18 $5.88.”

According to TipRanks.com, Arce is a 4-star analyst with an average return of 5.8% and a 35.1% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Entasis Therapeutics Holdings Inc with a $18 average price target.

Trillium Therapeutics (TRIL)

In a report released today, Swayampakula Ramakanth from H.C. Wainwright downgraded Trillium Therapeutics to Hold. The company’s shares closed last Monday at $0.28, close to its 52-week low of $0.24.

Ramakanth observed:

“We downgrade our rating of TRIL to and considering the high financial risk and the likely significant dilution from future stock offerings, limited visibility of company’s pipeline development strategy, and the ongoing transition of senior management, we are not comfortable to determine a specific price target. (1) financial; (2) clinical; (3) commercial; (4) partnership; and (5) legal and intellectual property. Trillium Therapeutics, Inc.”

According to TipRanks.com, Ramakanth ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -12.0% and a 27.1% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Zomedica Pharmaceuticals Corp, IntelGenx Technologies, and Gritstone Oncology Inc.

Trillium Therapeutics has an analyst consensus of Moderate Buy.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.